<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04237649</url>
  </required_header>
  <id_info>
    <org_study_id>CKAZ954A12101</org_study_id>
    <nct_id>NCT04237649</nct_id>
  </id_info>
  <brief_title>KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors</brief_title>
  <official_title>A Phase I/Ib, Open-label, Multi-center, Study of KAZ954 as a Single Agent and in Combination With Spartalizumab, NZV930 and NIR178 in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to explore the clinical utility of several therapies in patients&#xD;
      with advanced cancer.&#xD;
&#xD;
      This is a multi-center, open-label Phase I/Ib study. The study consists of a dose escalation&#xD;
      part, a dose expansion part testing KAZ954 as a single agent or KAZ954 in combination with&#xD;
      PDR001, NZV930 and NIR178. The dose escalation parts will estimate the MTD and/or RD and test&#xD;
      different dosing schedules.&#xD;
&#xD;
      The dose expansion parts of the study will use the MTD/RDE determined in the dose escalation&#xD;
      part to assess the activity, safety and tolerability of the investigational products in&#xD;
      patients with specific types of cancer.&#xD;
&#xD;
      Approximately 135 adult patients with advanced solid tumors will be enrolled.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 20, 2020</start_date>
  <completion_date type="Anticipated">August 12, 2024</completion_date>
  <primary_completion_date type="Anticipated">August 12, 2024</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Dose Limiting Toxicities (DLTs)</measure>
    <time_frame>35 days</time_frame>
    <description>Dose Limiting Toxicities</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse events and serious adverse events</measure>
    <time_frame>36 months</time_frame>
    <description>Incidence of adverse events is defined as number of participants with adverse events (AEs) and serious adverse events (SAEs), including changes from baseline in vital signs, electrocardiograms (ECGs) and laboratory results qualifying and reported as AEs.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with dose interruptions and dose reductions</measure>
    <time_frame>36 months</time_frame>
    <description>Number of participants with at least one dose interruption or reduction during study treatment to assess tolerability.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose intensity of study treatment</measure>
    <time_frame>36 months</time_frame>
    <description>Dose intensity computed as the ratio of actual cumulative dose received and actual duration of exposure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>36 months</time_frame>
    <description>per RECIST v1.1 and iRECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration profiles of KAZ954 as a single agent Cmax</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of KAZ954 in combination with PDR001 and derived PK parameters Cmax</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration of KAZ954 in combination with NZV930 and derived PK parameters Cmax</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum/Plasma concentration of KAZ954 in combination with NIR178 Cmax</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence and titer of anti-KAZ954 antibodies</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence and titer of anti-PDR001 antibodies</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence and titer of anti-NZV930 antibodies</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration profiles of KAZ954 as a single agent AUC</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration profiles of KAZ954 in combination with PDR001 and derived PK parameters AUC</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration profiles of KAZ954 incombination with NZV930 and derived PK parameters AUC</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum/Plasma concentration profiles of KAZ954 in combination with NIR178 and derived PK parameters AUC</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess the correlation between PD-L1 expression level in tumor using a validated assay and response to KAZ954 and in combo with PDR001, NIR178 or NZV930</measure>
    <time_frame>36 months</time_frame>
    <description>Expression of PD-L1, and determination of ORR &amp; PFS per RECIST 1.1 and iRECIST.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">145</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KAZ954</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KAZ954 + PDR001</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KAZ954 + NIR178</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>KAZ954 + NZV930</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KAZ954</intervention_name>
    <description>KAZ954 will be administered in every arm.</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_label>Arm C</arm_group_label>
    <arm_group_label>Arm D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PDR001</intervention_name>
    <description>KAZ954 + PDR001</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NIR178</intervention_name>
    <description>KAZ954 + NIR178</description>
    <arm_group_label>Arm C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NZV930</intervention_name>
    <description>KAZ954 + NZV930</description>
    <arm_group_label>Arm D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients with metastatic and/or advanced malignancies not amenable to curative treatment by&#xD;
        surgery.&#xD;
&#xD;
        Must have a site of disease amenable to biopsy and be a candidate for tumor biopsy&#xD;
        according to the treating institution's guidelines. Patient must be willing to undergo a&#xD;
        new tumor biopsy at screening and during the study.&#xD;
&#xD;
        ECOG Performance Status of &lt;2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Presence of symptomatic central nervous system (CNS) metastases, or CNS metastases that&#xD;
        require concurrent treatment - including surgery, radiation and/or corticosteroids.&#xD;
&#xD;
        History of severe hypersensitivity reaction to any ingredient of study drug(s) and other&#xD;
        mAbs and/or their excipients.&#xD;
&#xD;
        Impaired cardiac function HIV Known history of tuberculosis Systemic chronic steroid&#xD;
        therapy&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California at Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maggie Lindenbaum</last_name>
      <phone>800-825-2631</phone>
      <email>mlindenbaum@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Zev A. Wainberg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale University Yale Cancer Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Ciezniak</last_name>
      <phone>203-737-7059</phone>
      <email>jessica.ciezniak@yale.edu</email>
    </contact>
    <investigator>
      <last_name>Patricia M LoRusso</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University Medical School</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angel C Rivera</last_name>
      <phone>312-926-7358</phone>
      <email>angel.rivera@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Devalingam Mahalingam</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine Dept. of Siteman Cancer Center</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>314-747-3575</phone>
    </contact>
    <investigator>
      <last_name>Haeseong Park</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arslan Ali Khan</last_name>
      <phone>+1 713 792 2921</phone>
      <email>aakhan4@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Shubham Pant</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shatin, New Territories</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sunto Gun</city>
        <state>Shizuoka</state>
        <zip>411 8777</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>119074</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barcelona</city>
        <state>Catalunya</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Hong Kong</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>January 17, 2020</study_first_submitted>
  <study_first_submitted_qc>January 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 23, 2020</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Solid Tumors</keyword>
  <keyword>KAZ954</keyword>
  <keyword>PDR001</keyword>
  <keyword>Spartalizumab</keyword>
  <keyword>NIR178</keyword>
  <keyword>NZV930</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Phase I/Ib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spartalizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

